Bone Biologics (BBLG) Competitors

$1.23 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.54%)

As of 06:49 PM Eastern

BBLG vs. INBS, TNON, NDRA, NXL, and NVNO

Should you buy Bone Biologics stock or one of its competitors? MarketBeat compares Bone Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bone Biologics include Intelligent Bio Solutions (INBS), Tenon Medical (TNON), ENDRA Life Sciences (NDRA), Nexalin Technology (NXL), and enVVeno Medical (NVNO). These companies are all part of the "medical equipment" industry.

How does Bone Biologics compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Bone Biologics has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Bone Biologics' return on equity of -50.47% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-296.73%	-176.09%	-89.71%
Bone Biologics	N/A	-50.47%	-47.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics has lower revenue, but higher earnings than Intelligent Bio Solutions. Bone Biologics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$3.05M	2.06	-$10.57M	-$12.22	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, Bone Biologics had 6 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 7 mentions for Bone Biologics and 1 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 1.19 beat Bone Biologics' score of 0.75 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intelligent Bio Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bone Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 6.1% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Intelligent Bio Solutions has a beta of 4.24, meaning that its stock price is 324% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Summary

Bone Biologics beats Intelligent Bio Solutions on 8 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to Tenon Medical?

Tenon Medical (NASDAQ:TNON) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Tenon Medical has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Bone Biologics has lower revenue, but higher earnings than Tenon Medical. Tenon Medical is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenon Medical	$3.94M	2.10	-$12.56M	-$1.29	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, Bone Biologics had 6 more articles in the media than Tenon Medical. MarketBeat recorded 7 mentions for Bone Biologics and 1 mentions for Tenon Medical. Bone Biologics' average media sentiment score of 0.75 beat Tenon Medical's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenon Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bone Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.7% of Tenon Medical shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.3% of Tenon Medical shares are owned by insiders. Comparatively, 6.1% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bone Biologics has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Bone Biologics' return on equity of -50.47% beat Tenon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenon Medical	-270.09%	-907.60%	-110.17%
Bone Biologics	N/A	-50.47%	-47.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bone Biologics beats Tenon Medical on 9 of the 14 factors compared between the two stocks.

How does Bone Biologics compare to ENDRA Life Sciences?

Bone Biologics (NASDAQ:BBLG) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, Bone Biologics had 4 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 7 mentions for Bone Biologics and 3 mentions for ENDRA Life Sciences. Bone Biologics' average media sentiment score of 0.75 beat ENDRA Life Sciences' score of 0.60 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bone Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

ENDRA Life Sciences has a consensus target price of $30.00, indicating a potential upside of 460.75%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 6.1% of Bone Biologics shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Bone Biologics beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.

How does Bone Biologics compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

In the previous week, Bone Biologics had 3 more articles in the media than Nexalin Technology. MarketBeat recorded 7 mentions for Bone Biologics and 4 mentions for Nexalin Technology. Bone Biologics' average media sentiment score of 0.75 beat Nexalin Technology's score of 0.27 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bone Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bone Biologics has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Bone Biologics' return on equity of -50.47% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Bone Biologics	N/A	-50.47%	-47.40%

Bone Biologics has lower revenue, but higher earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	27.37	-$8.22M	-$0.47	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 6.1% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has a beta of 3.56, meaning that its stock price is 256% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Summary

Bone Biologics beats Nexalin Technology on 8 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to enVVeno Medical?

Bone Biologics (NASDAQ:BBLG) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 6.1% of Bone Biologics shares are owned by insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bone Biologics had 7 more articles in the media than enVVeno Medical. MarketBeat recorded 7 mentions for Bone Biologics and 0 mentions for enVVeno Medical. Bone Biologics' average media sentiment score of 0.75 beat enVVeno Medical's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Positive
enVVeno Medical	Neutral

Bone Biologics' return on equity of -50.47% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
enVVeno Medical	N/A	-66.39%	-60.42%

Bone Biologics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Bone Biologics is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A

Summary

Bone Biologics beats enVVeno Medical on 6 of the 11 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.21M	$3.33B	$6.34B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	-0.54	18.53	21.09	25.40
Price / Sales	N/A	289.80	527.81	78.77
Price / Cash	N/A	129.82	44.13	56.13
Price / Book	0.47	6.90	9.99	7.01
Net Income	-$3.11M	$24.23M	$3.55B	$335.05M
7 Day Performance	-3.15%	0.59%	0.42%	-0.29%
1 Month Performance	-12.14%	-0.61%	-0.05%	1.15%
1 Year Performance	-77.51%	63.26%	35.06%	34.79%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	1.2008 of 5 stars	$1.23 flat	N/A	-76.7%	$2.21M	N/A	N/A	2	Earnings Report Analyst Revision High Trading Volume
INBS Intelligent Bio Solutions	0.8399 of 5 stars	$4.11 +3.0%	N/A	-77.9%	$8.22M	$3.05M	N/A	10	Gap Up
TNON Tenon Medical	0.6337 of 5 stars	$0.72 +0.6%	N/A	-39.7%	$8.18M	$3.94M	N/A	8	Gap Up
NDRA ENDRA Life Sciences	3.1253 of 5 stars	$5.74 +1.4%	$30.00 +422.6%	+79.0%	$7.12M	N/A	N/A	20	Earnings Report
NXL Nexalin Technology	0.5903 of 5 stars	$0.34 -0.1%	N/A	-72.8%	$7.00M	$300K	N/A	3	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. INBS, TNON, NDRA, NXL, and NVNO

How does Bone Biologics compare to Intelligent Bio Solutions?

Summary

How does Bone Biologics compare to Tenon Medical?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Summary

How does Bone Biologics compare to Nexalin Technology?

Summary

How does Bone Biologics compare to enVVeno Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. INBS, TNON, NDRA, NXL, and NVNO

How does Bone Biologics compare to Intelligent Bio Solutions?

Is INBS or BBLG more profitable?

Do analysts recommend INBS or BBLG?

Which has stronger valuation and earnings, INBS or BBLG?

Does the media favor INBS or BBLG?

Do insiders & institutionals believe in INBS or BBLG?

Which has more volatility and risk, INBS or BBLG?

Summary

How does Bone Biologics compare to Tenon Medical?

Which has more risk and volatility, TNON or BBLG?

Which has preferable valuation and earnings, TNON or BBLG?

Does the media favor TNON or BBLG?

Do institutionals & insiders hold more shares of TNON or BBLG?

Is TNON or BBLG more profitable?

Do analysts recommend TNON or BBLG?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Is BBLG or NDRA more profitable?

Does the media prefer BBLG or NDRA?

Which has stronger earnings & valuation, BBLG or NDRA?

Do analysts rate BBLG or NDRA?

Which has more volatility & risk, BBLG or NDRA?

Do institutionals & insiders hold more shares of BBLG or NDRA?

Summary

How does Bone Biologics compare to Nexalin Technology?

Does the media favor NXL or BBLG?

Is NXL or BBLG more profitable?

Which has stronger earnings & valuation, NXL or BBLG?

Do institutionals & insiders have more ownership in NXL or BBLG?

Do analysts prefer NXL or BBLG?

Which has more volatility & risk, NXL or BBLG?

Summary

How does Bone Biologics compare to enVVeno Medical?

Do analysts rate BBLG or NVNO?

Do insiders and institutionals hold more shares of BBLG or NVNO?

Does the media refer more to BBLG or NVNO?

Is BBLG or NVNO more profitable?

Which has more volatility and risk, BBLG or NVNO?

Which has better valuation and earnings, BBLG or NVNO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools